Department of Physical Medicine and Rehabilitation, Istanbul Medipol University, International School of Medicine, Istanbul, Turkey.
Çukurova State Hospital, Physical Medicine and Rehabilitation Clinic, Adana, Turkey.
Clin Ther. 2024 Aug;46(8):e1-e5. doi: 10.1016/j.clinthera.2024.05.004. Epub 2024 Jun 22.
Musculoskeletal pain may occur after becoming infected with SARS-Cov2. This study was designed to evaluate the efficacy of mesotherapy in treating chronic pain following COVID-19 infection.
A retrospective review was conducted of the records of 96 patients with post-COVID pain syndrome. Those who were eligible for oral therapy or mesotherapy, included in the study. Patients receiving oral treatment with diclofenac potassium, thiocolchicoside and cyanocobalamin were included in one group (n = 46), and patients receiving intradermal mesotherapy with 2% lidocaine + cyanocobalamin were included in another group (n = 50). The results of the Visual Analogue Scale (VAS) and the Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) were individually assessed before and one week after the treatment.
The participants were 40.2 ± 11.1 years old on average. Of the participants, 35.4% (n = 34) were male and 64.6% (n = 62) were female. Before treatment, there was no statistically significant difference between the patients in terms of VAS and LANSS scores. Following the treatment, a notable positive response was observed in both groups. Nevertheless, when compared to the oral treatment group, the mesotherapy group exhibited a more pronounced enhancement in VAS and LANSS scores (P < 0.001, P < 0.001, respectively).
While both mesotherapy and oral therapy offer benefits in reducing pain and alleviating neuropathic symptoms in post-COVID pain syndrome, mesotherapy stands out as an especially effective and well-tolerated treatment method, surpassing the efficacy of the oral alternative.
感染 SARS-CoV-2 后可能会出现肌肉骨骼疼痛。本研究旨在评估中胚层疗法治疗 COVID-19 感染后慢性疼痛的疗效。
对 96 例 COVID 后疼痛综合征患者的记录进行回顾性分析。选择符合条件的口服治疗或中胚层治疗患者纳入研究。一组纳入接受双氯芬酸钾、硫代秋水仙碱和氰钴胺口服治疗的患者（n=46），另一组纳入接受 2%利多卡因+氰钴胺皮内中胚层治疗的患者（n=50）。分别在治疗前和治疗后一周评估视觉模拟评分（VAS）和利兹神经病症状和体征评估（LANSS）的结果。
参与者平均年龄为 40.2±11.1 岁。其中 35.4%（n=34）为男性，64.6%（n=62）为女性。治疗前，两组患者的 VAS 和 LANSS 评分无统计学差异。治疗后，两组均有明显的阳性反应。然而，与口服治疗组相比，中胚层治疗组的 VAS 和 LANSS 评分改善更显著（P<0.001，P<0.001）。
虽然中胚层治疗和口服治疗都能有效减轻 COVID 后疼痛综合征患者的疼痛和神经病理性症状，但中胚层治疗是一种更有效、耐受性更好的治疗方法，优于口服治疗。
